Tempus AI (TEM) has introduced the next-generation of its agentic AI platform for oncology drug development, Lens, the company said over the weekend.
The platform was designed to help drug development teams to design better clinical trials, target patient subgroups, and generate evidence more quickly, Tempus AI said.